An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma

Enrolling by invitation

Conditions studied: Digestive Oncology

In brief

The investigators plan to develop a deep learning-based automatic interpretation model for Claudin18.2(CLDN18.2) using the institution's and multiple other centers' extensive pathological resources of digestive system adenocarcinomas. This study will not only strictly follow the latest domestic expert consensus and standards, but also aims to address current pain points in manual interpretation. It seeks to provide technical support for standardizing, objectifying, and streamlining CLDN18.2 testing, thereby advancing the application of precision medicine in the diagnosis and treatment of digestive system diseases. The project has clear clinical necessity and broad application prospects.

Key facts

Study ID

NCT07274579

Run by

Nanfang Hospital, Southern Medical University

People needed

2000

Starts

2025-10-01

Expected to finish

2028-08-01

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age over 18 years.
• Patients who underwent CLDN18.2 immunohistochemistry and H\&E staining.
• Availability of complete pathology reports and clinical information.

You may not qualify if…

• Patients with missing data or specimens not meeting quality control requirements for analysis.

Where it is running

• Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong, China
• Qianfoshan Hospital — Jinan, Shandong, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.